These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33994798)

  • 21. Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis
    Zhou R; Song L; Zhang W; Shao L; Li X; Li X
    Onco Targets Ther; 2021; 14():2847-2851. PubMed ID: 33958875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.
    Duggirala KB; Lee Y; Lee K
    Biomol Ther (Seoul); 2022 Jan; 30(1):19-27. PubMed ID: 34074804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
    Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
    Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Patient with Three EGFR Mutations - Gradual Development of Resistance to Previous Targeted Treatment].
    Svatoň M; Pešek M; Baxa J; Mukenšnabl P; Benešová L; Minárik M
    Klin Onkol; 2017; 31(1):53-58. PubMed ID: 29488779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
    Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
    J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired
    He W; Tong L; Yang W; Yuan Y; Li Y; Tang W
    Front Oncol; 2024; 14():1298389. PubMed ID: 38903714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-Generation
    Sullivan I; Planchard D
    Front Med (Lausanne); 2016; 3():76. PubMed ID: 28149837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.
    Nakamura T; Nakashima C; Komiya K; Kitera K; Hirai M; Kimura S; Aragane N
    PLoS One; 2018; 13(12):e0209384. PubMed ID: 30550608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.
    Tamiya M; Fujikawa K; Suzuki H; Yokoyama T; Uenami T; Tamiya A; Sato Y; Saito G; Uchida J; Morita M; Hirashima T; Fukuda Y; Kanazu M; Hosoya K; Suzuki T; Ueno K; Fujimoto D; Kumagai T; Teramukai S
    Invest New Drugs; 2022 Apr; 40(2):361-369. PubMed ID: 35088212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024).
    Das D; Xie L; Hong J
    RSC Med Chem; 2024 Aug; 15(10):3371-94. PubMed ID: 39246743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy.
    Gan J; Huang Y; Liao J; Pang L; Fang W
    Onco Targets Ther; 2021; 14():5297-5307. PubMed ID: 34824536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
    Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
    Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.
    Wang Y; Han R; Zhu M; He T; He Y
    Front Oncol; 2022; 12():875313. PubMed ID: 35530305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
    Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
    Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
    Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
    J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation
    Lai M; Zhang T; Chen H; Song P; Tong L; Chen J; Liu Y; Ning Y; Feng F; Li Y; Tang H; Chen Y; Fang Y; Lu X; Geng M; Ding K; Yu K; Ding J; Xie H
    J Cancer; 2023; 14(1):152-162. PubMed ID: 36605493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.